|
AD Connect
User
Home
Discussions
Datasets
Tech Help
Events
Video Library
FDSA
Datasets
Datasets
Datasets
Forums
Tags
More
Cancel
New
Dataset Categories Navigation
-
Datasets
-
Region
+
Clinical Trial
+
Data Type
+
Disease
Africa
Asia
Europe
Middle East
North America
Oceania
South America
Datasets
Datasets
Region
Datasets
A double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone on cognition in subjects with mild to moderate Alzheimer's disease
What is it and what does it include? This phase II study was designed to determine the safety profile and treatment effects of rosiglitazone (RSG) in subjects with mild to moderate Alzheimer’s disease…
A blood based 12-miRNA signature of Alzheimer patients - GSE46579
What is it and what does it include? Investigators in this study applied Next-Generation Sequencing (NGS) to miRNAs from blood samples of 48 AD patients and 22 unaffected controls, yielding a total of…
Alzheimer's Disease and Healthy Aging Data
The Alzheimer’s Disease and Healthy Aging Data provides access to national and state level CDC data on a range of key indicators of health and well-being for older adults, including: Caregiving, Subjective…
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease
What is it and what does it include? The study included 124 people between the ages of 50 and 80 with mild to moderate Alzheimer's disease and compared 250 mg of Rilapladib taken once daily to placebo…
A Study of Semagacestat for Alzheimer's Patients
The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment. Baseline for the efficacy measures is…
